The peer-reviewed framework utilizes cough acoustics to achieve 0.96 AUROC in COPD detection; CEO Echo Chen, PhD, outlines expansion into major chronic and acute respiratory disease pipelines SHANGHAI — March 2, 2026 — Luca Healthcare, a global innovator in AI-driven health solutions, today announced the publication of its breakthrough AI research in the high-impact journal npj Digital Medicine. The article, titled “A device-invariant multi-modal learning framework for respiratory disease classification,” marks a pivotal shift in digital health by solving the “hardware hurdle”—ensuring that diagnostic accuracy remains consistent regardless of the smartphone or recording device used.
The Primary Breakthrough: Cough as a Clinical Biomarker
The publication details a first-of-its-kind AI framework that analyzes cough sounds—complex bio-acoustic signatures—to identify respiratory pathologies. Unlike traditional models that are often tethered to specific high-end hardware, Luca’s framework employs an adversarial branch and invariant risk minimization (IRM) to strip away “device noise.”
This allows the AI to extract pure physiological data from any microphone, achieving a superior 0.9698 AUROC for COPD identification.
The Secondary Key: Universal Scalability
Historically, “device effect” has been the primary barrier to the global scaling of digital biomarkers. Luca’s framework proves that high-fidelity diagnostics can be delivered via any mobile device, unlocking massive market potential in both developed healthcare systems and low-resource settings.
Executive Commentary
“Cough sounds are bio-signatures that hold the potential to solve a global respiratory crisis affecting over 750 million people with chronic diseases and over 1 billion with acute infections annually,” said Echo Chen, PhD, CEO of Luca Healthcare. “This publication in Nature npj Digital Medicine is a testament to our success in building a device-invariant foundation. Having validated this framework in COPD, we are now aggressively expanding our pipeline to include other major chronic respiratory diseases and acute infection diagnostics, ensuring our technology serves as a universal ‘digital stethoscope’ for the 21st century.”
Strategic Roadmap: Beyond COPD
While the study highlights a gold-standard performance in COPD and Lower Respiratory Tract Infections (LRTI), Luca Healthcare is leveraging this same device-invariant technology to address:
- Chronic Diseases: Expanding into Asthma, Bronchiectasis, and Pulmonary Fibrosis monitoring
- Decentralized Clinical Trials: Providing pharmaceutical partners with a standardized, hardware-agnostic tool to measure drug efficacy remotely
- Acute Infections: Developing rapid screening for Pneumonia and other viral respiratory tract infections